

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ARTICLE

An Efficient Synthesis of Weinreb Amides and Ketones via Palladium Nanoparticles on ZIF-8 Catalysed Carbonylative Coupling[†]

Cite this: DOI: 10.1039/x0xx00000x

Tuan Thanh Dang, Anqi Chen and Abdul Majeed Seayad*

Received 00th January 2012,

Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Heterogeneously catalysed carbonylative coupling reactions such as aminocarbonylation and Suzuki-carbonylation are reported using Pd nanoparticles supported on ZIF-8 as efficient and environmentally attractive synthesis of Weinreb amides and ketones from aryl bromides or iodides. The catalyst is air stable, offers high activity with very low palladium leaching and is recyclable. Presence of a phosphine ligand was required with aryl bromides as substrates, while no ligand was necessary when aryl iodides were used.

Introduction

Carbonylative coupling is an environmentally attractive three-component methodology to synthesize several value added carbonyl functionalised compounds such as carboxylic acid/esters, amides, ketones, etc. from readily available starting materials.¹ Among amides, an important class is the Weinreb amides (*N*-methoxy-*N*-methyl amides) that are widely used as acylating agents to afford a variety of value added carbonyl compounds having applications in the syntheses of complex natural products, pharmaceuticals and fine chemicals.² In the conventional method, Weinreb amides are produced by the direct reaction of *N,O*-dimethylhydroxylamine hydrochloride (DMHA.HCl) with an acid chloride in the presence of a base.³ Other acid derivatives such as anhydrides, lactones, esters and amides could also be used.^{2,4} Direct reaction of carboxylic acids with DMHA could be a simple alternative, however this requires various coupling agents to generate the activated carbonyl component for coupling,⁵ thus making it environmentally unattractive. Under this context, aminocarbonylation⁶ strategy in which an activated metal-acyl complex is catalytically generated in situ for coupling with DMHA offers an environmentally benign method for Weinreb amide synthesis. In spite of its advantages only a few reports⁷⁻¹⁰ were available on this promising reaction, mainly using homogeneous palladium catalysts.


Buchwald and co-workers⁷ reported an efficient catalyst system comprising of Pd(OAc)₂ in the presence of Xantphos as a ligand to afford a variety of Weinreb amides in up to 99% yield from the corresponding aryl bromides under atmospheric pressure of carbon monoxide at 80 °C. The same catalyst

system was used by Odell and co-workers⁸ in the presence of Mo(CO)₆ or W(CO)₆ as a carbon monoxide source under microwave irradiation conditions and by Venturello and co-workers⁹ to synthesise α,β -unsaturated Weinreb amides from the corresponding heterocyclic triflates. Recently, Kollár and co-workers reported Pd(OAc)₂ in the presence of PPh₃ as an alternative homogeneous catalyst for aryl and alkenyl iodides as substrates, however at 40 – 60 bar pressure of carbon monoxide.¹⁰ Most of these homogeneously catalyzed aminocarbonylation reactions to synthesize Weinreb amides have the obvious disadvantage of separation of the catalyst from the product and its subsequent recycle. In addition, small amounts of palladium residues in the product would be a concern for pharmaceutical applications. Hence, an efficient heterogeneous catalyst system is required to make this promising aminocarbonylation strategy as an industrially viable and sustainable alternative route to Weinreb amide synthesis. However, to the best of our knowledge, a promising heterogeneous catalyst system for this purpose is not reported so far. Recently, we have reported palladium nanoparticles supported on MOF-5 (Metal Organic Framework)¹¹ and ZIF-8 (Zeolitic Imidazolate Framework)¹² as promising heterogeneous catalysts for the synthesis of various amides under aminocarbonylation conditions.¹³ Herein, we report an easy and environmentally attractive synthesis of various functionalised Weinreb amides from the corresponding aryl bromides or iodides following aminocarbonylation strategy in the presence of recyclable palladium nanoparticles supported on ZIF-8 (Pd/ZIF-8) as an efficient catalyst. The efficiency of the catalyst system was also demonstrated for the synthesis of ketones using Suzuki-carbonylation strategy.

Results and discussion


An initial investigation showed that synthesis of the Weinreb amide, *N*-methoxy-*N*,4-dimethylbenzamide (**2a**) could be achieved in up to 72% yield from *p*-bromotoluene (**1a**) as a standard substrate and DMHA.HCl using 1 wt.% Pd/ZIF-8¹⁴ as the catalyst in the presence of dpePhos as a ligand and K₂CO₃ as a base at 3 bar of carbon monoxide and 105 °C after 12 h of reaction (Table 1, entry 1).

Table 1. Optimizations of aminocarbonylation of *p*-bromotoluene with *N*,*O*-dimethylhydroxyamine hydrochloride.^[a]



X = Br (**1a**) or I (**1a'**)

Ligands used when aryl bromides were used as substrate



Entry	Base	P _{CO} (bar)	Ligand	Catalyst	Yield (%) ^[b]
1	K ₂ CO ₃	3	dpePhos	Pd/ZIF-8	72
2	K ₂ CO ₃	3	PPh ₃	Pd/ZIF-8	12
3	K ₂ CO ₃	3	dppf	Pd/ZIF-8	38
4	K ₂ CO ₃	3	dppp	Pd/ZIF-8	14
5	K ₂ CO ₃	3	BINAP	Pd/ZIF-8	19
6	K ₂ CO ₃	3	Xantphos	Pd/ZIF-8	>99
7	K ₂ CO ₃	1	Xantphos	Pd/ZIF-8	99
8	Na ₂ CO ₃	1	Xantphos	Pd/ZIF-8	96
9	K ₃ PO ₄	1	Xantphos	Pd/ZIF-8	23
10	Et ₃ N	1	Xantphos	Pd/ZIF-8	68
11	(<i>i</i> -Pr) ₂ NEt	1	Xantphos	Pd/ZIF-8	92
12	K ₂ CO ₃	1	Xantphos	Pd/MOF-5	95
13	K ₂ CO ₃	1	Xantphos	Pd/MCM-41	75
14	K ₂ CO ₃	1	-	Pd/ZIF-8	92 ^[c]
15	K ₂ CO ₃	3	-	Pd/ZIF-8	>99 ^[c]

^[a] Conditions: *p*-bromotoluene (**1a**, 1 mmol), *N*,*O*-dimethylhydroxyamine hydrochloride (DMHA.HCl, 1.5 mmol), 1 wt.% Pd/ZIF-8 (24 mg, 0.21 mol%), ligand (1 mol%), K₂CO₃ (2.5 equiv.), toluene (2 mL), 105 °C, 12 h.



^[b] Yield was determined by ¹H-NMR using mesitylene as an internal standard. ^[c] *p*-Iodotoluene (**1a'**) was used as the substrate.

A ligand optimization study (Table 1) showed that, under these conditions, common ligands such as PPh₃, dppf, dppp, and BINAP provided lower yields (<40%) of the desired product (entries 2-5), while quantitative yield was achieved when Xantphos was used as the ligand. To our delight, near quantitative yield was also achieved even at 1 bar pressure of carbon monoxide using Xantphos as the ligand (entry 7). Among the bases screened, K₂CO₃ performed the best and Na₂CO₃ was also effective with only a slight decrease in the yield (96%). However, when K₃PO₄ was used, the yield decreased drastically to 23%. Soluble organic bases can also be used and up to 68% and 92% yields were observed in the presence of triethylamine and Hünig base, respectively. Pd/MOF-5 as a catalyst gave a comparable yield of 95%, while Pd/MCM-41 gave a lower yield of 75%. Interestingly, no ligand was necessary when *p*-iodotoluene (**1a'**) was used as the

substrate at atmospheric pressure of CO and up to 92% yield was achieved at 1 bar of carbon monoxide and was increased to quantitative yield upon increasing the pressure to 3 bar.

Next, we applied these optimized conditions to explore the synthesis of various functionalized Weinreb amides from the corresponding functionalized aryl bromides and iodides. Initially, relatively inexpensive and readily available aryl bromides were chosen as substrates in the presence of Xantphos ligand at 3 bar pressure of carbon monoxide to ensure higher conversion when less reactive aryl bromides were also used. Good to excellent isolated yields were obtained with unsubstituted (**1b**) and *para*-substituted (**1a**, **1c**, and **1g-k**) aryl bromides. Sterically demanding *o*-Me substituted aryl bromide (**1d**) gave up to 75% yield of **2d**. Mono- and multi-methoxy substituents at various positions of the aromatic ring (**1e** and **1f**) were well tolerated and the corresponding Weinreb amides **2e** and **2f** were obtained in 94-96% yields.

Table 2. Synthesis of Weinreb amides from aryl bromides using Pd/ZIF-8 catalyzed aminocarbonylation.^[a]

ArBr + CO + HN(Me)OMe.HCl → Ar-C(=O)-N(Me)OMe (2(a-o))

Conditions: 1 wt.% Pd/ZIF-8, Xantphos, K₂CO₃, toluene, 105 °C, 12 h.

Yields: **2a**: 97%, **2b**: 95%, **2c**: 94%, **2d**: 75%, **2e**: 96%, **2f**: 95%, **2g**: 94%, **2h**: 77%, **2i**: 79%, **2j**: 98%, **2k**: 68%^[b], **2l**: 84%, **2m**: 78%, **2n**: 95%, **2o**: 98%


^[a] Conditions: Aryl bromide (**1(a-o)**, 1 mmol), *N*,*O*-dimethylhydroxyamine hydrochloride (DMHA.HCl, 1.5 mmol), 1 wt.% Pd/ZIF-8 (24 mg, 0.21 mol%), Xantphos (1 mol%), K₂CO₃ (2.5 equiv.), toluene (2 mL), CO (3 bar), 105 °C, 12 h. Isolated yields are given. ^[b] incomplete conversion observed.

Presence of other halogen atoms such *p*-Cl and *p*-F was also tolerated and the products **2g** and **2h** were formed in 95% and 77% yields, respectively. Electron withdrawing NO₂ substituent gave **2i** in good yield of 79%, whereas up to 98% yield of **2j** was achieved from *p*-CN substituted aryl bromide. Unprotected amino (**1k**), aldehyde (**1l**) and keto (**1m**) groups at *para* position were well tolerated and the corresponding Weinreb

amides **2k**, **2l** and **2m** were obtained in 68%, 84% and 78%, respectively, demonstrating good functional group compatibility of the catalyst system. Heteroaromatic Weinreb amides **2n** and **2o** were also easily obtained in excellent yields from the corresponding heteroaryl bromides **1n** and **1o** using the present catalyst system.


More reactive aryl iodides as the substrate did not require phosphine ligands under the present aminocarbonylation conditions and various functionalized Weinreb amides were obtained in good to excellent yields at 3 bar pressure of carbon monoxide at 105 °C as shown in Table 3. Similar to the case of aryl bromides, several functional groups were tolerated including nitro (**2i**), hydroxy (**2p**), and carbonyl (**2q**) groups.

Table 3. Synthesis of Weinreb amides from aryl iodides using Pd/ZIF-8 catalyzed aminocarbonylation.^[a]



^[a] Conditions: Aryl iodide (1 mmol), *N,O*-dimethylhydroxylamine hydrochloride (DMHA.HCl, 1.5 mmol), 1 wt.% Pd/ZIF-8 (24 mg, 0.21 mol%), Xantphos (1 mol%), K_2CO_3 (2.5 equiv.), toluene (2 mL), CO (3 bar), 105 °C, 12 h. Isolated yields are given. ^[b] incomplete conversion observed.

Interestingly, bromide as a functional group was well tolerated under ligand free condition and the *para*- and *meta*-bromo-substituted Weinreb amides **2r** and **2s** were obtained in up to 88% isolated yields. The bromo-substituted Weinreb amides can be further functionalized using common protocols to afford several value added products and intermediates. For instance, 4-bromobenzophenone (**3**) was prepared in 82% isolated yield from 4-bromo-*N*-methoxy-*N*-methylbenzamide (**2r**) by reaction with phenyl magnesium bromide (Scheme 1) and was further coupled with acetamide using copper catalyst¹⁵ affording *N*-(4-benzoylphenyl)acetamide (**4**), an intermediate for the synthesis of Mebendazole¹⁶ (**5**), which is an antihelmintic drug.



Scheme 1. Synthesis of Mebendazole from 4-bromo-*N*-methoxy-*N*-methylbenzamide.

Direct synthesis of ketone is possible if DMHA.HCl is replaced with a suitable coupling partner. Accordingly, Suzuki-carbonylation¹⁷ was examined using iodobenzene (**6**) and *p*-methoxyphenylboronic acid (**7**) as the standard substrates under the optimized carbonylation condition using 1 wt.% Pd/ZIF-8 as the catalyst in the absence of ligands. As shown in Table 4, the product ketone (**8**) was obtained in up to 55% yield, however, the biaryl **9** was formed as a side product in substantial amount when inorganic bases were used (Entries 1-4, Table 4). To our delight, formation of the **9** by the direct coupling between aryl iodide and aryl boronic acid was completely suppressed when organic bases such as Hünig base and triethylamine were used and the product **8** was obtained in 36% and 42% yields respectively. The yield was further improved to 85% when 6 bar pressure of carbon monoxide was used with the reaction time prolonged to 24 h (Entry 7, Table 4).

Table 4. Synthesis of ketone via Suzuki-carbonylation of iodobenzene.^[a]


Reaction scheme for Table 4: Iodobenzene (**6**) + CO + $\text{B}(\text{OH})_2$ (**7**) reacts with 1 wt.% Pd/ZIF-8, toluene, base at 105 °C to form ketone (**8**) and biaryl (**9**).

Entry	Base	P_{CO} (bar)	Time (h)	Yield, % ^[b]	
				8	9
1	K_2CO_3	3	12	46	30
2	K_3PO_4	3	12	55	22
3	Na_2CO_3	3	12	46	25
4	NaHCO_3	3	12	12	4
5	(<i>i</i> -Pr) ₂ NEt	3	12	36	n.d.
6	Et_3N	3	12	42	n.d.
7	Et_3N	6	24	85 ^[c]	n.d.

^[a] Conditions: iodobenzene (**6**, 0.5 mmol), *p*-methoxyphenylboronic acid (**7**, 1.5 equiv.), 1 wt.% Pd/ZIF-8 (24 mg, 0.42 mol%), base (2.5 equiv.), toluene (2 mL), 105 °C. ^[b] Yield was determined by GC using hexadecane as an internal standard. ^[c] 78% isolated yield.

With aryl bromide as a substrate, presence of a phosphine ligand was found to be necessary for Suzuki-carbonylation

using 1wt.% Pd/ZIF-8 as the catalyst. CataCXium A was found to be one of the best ligands under the present catalyst system in the presence of triethylamine as a base. As shown in Scheme 2, up to 74% yield to the ketone **11** was achieved at 10 bar of carbon monoxide for 18 h at 100 °C from bromobenzene **1b** and the boronic acid **10**.



Scheme 2. Suzuki-carbonylation of aryl bromides.

The 1wt.% Pd/ZIF-8 catalyst was found to be recyclable and no appreciable change in catalytic performance was observed after six cycles for the aminocarbonylation of *p*-iodotoluene. Very low palladium leaching (<3 ppm) was observed in each run. A filtrate test was carried out to investigate the possible involvement of homogeneously catalysed reaction. No appreciable reaction was observed when the filtrate of an aminocarbonylation reaction, after removing the solid catalyst, was subjected to a second aminocarbonylation reaction by adding fresh reaction mixture. This observation could possibly indicate that the catalytic reaction pathway originating from the leached out palladium leading to a homogeneous pathway may be much less important compared to a heterogeneous pathway.

When aryl bromides were used as a substrate for both amino- and Suzuki- carbonylations, presence of a suitable phosphine ligand was found to be necessary together with 1wt.% Pd/ZIF-8 as the catalyst. The adsorbed phosphine ligand onto palladium nanoparticles could alter the electronic properties to facilitate the activation of less reactive aryl bromides during the initial oxidative addition step.¹⁸ Though presence of phosphine ligands could potentially enhance leaching of palladium into solution thereby driving the reaction through homogeneous pathway, low leaching (<4 ppm)^{13a} and efficient recyclability of the catalyst observed shows either such homogeneous pathway is negligible owing to the stability¹⁹ of Pd/ZIF-8 catalyst or the efficient re-adsorption of palladium on to the support (ZIF-8) after a potential homogeneous reaction (quasi-heterogeneous catalysis).²⁰ Further mechanistic investigation is necessary to understand the dynamic nature of Pd nanoparticles²¹ and the appropriate share of heterogeneous and homogeneous reaction pathways in the absence and presence of ligands when Pd/ZIF-8 is used as a catalyst under the present reaction conditions.

The scalability of the reaction was also investigated using both *p*-bromo- and *p*-iodo-toluene (**1a** and **1a'**) under the

optimized conditions using 5 mmol of substrate using 24 mg of catalyst for 24 h, achieving a TON of about 1500 with about 68-70% yields.

Conclusions

We have reported an easy synthesis of Weinreb amides using an efficient and recyclable heterogeneous catalyst from the corresponding aryl bromides or iodides with *N,O*-dimethylhydroxyamine hydrochloride under relatively mild aminocarbonylation conditions. This procedure offers a sustainable alternative synthesis of various functionalized Weinreb amides in high yields. The potential application of this catalyst system has been demonstrated for the synthesis of an intermediate towards the synthesis of antihelmintic drug Mebendazole from the corresponding Weinreb amide. The possibility of direct synthesis of ketones by Suzuki-carbonylation was also demonstrated. The catalyst Pd/ZIF-8 could be efficiently recycled and the Pd leaching was found to be less than 3 ppm. Scale up possibility was also demonstrated in a gram scale achieving a TON of about 1500.

Experimental Section

General information

All chemicals and reagents were purchased from Aldrich or Alfa Aesar and were used without further purification. For chromatographic purifications, technical-grade solvents were used. Reactions were checked by thin layer chromatography (TLC) using *Merck Silica Gel 60 F254* plates under UV light. The chromatographic purification of the products was performed on *silica gel*. NMR-spectra were measured in the given solvent at room temperature on a *Bruker Avance 400* (400 MHz, ¹H-NMR; 100 MHz, ¹³C-NMR). Chemical shifts δ are given in parts per million (ppm) relative to tetramethylsilane (TMS) for ¹H- and ¹³C-NMR spectra and also calibrated against the solvent residual peak. Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad signal or as a combination of them. Coupling constants (*J*) are given in Hertz (Hz).

Preparation of 1wt.% Pd/ZIF-8 catalyst.^{13a}

K₂PdCl₄ (16.32 mg, 0.05 mmol) was dissolved in 30 mL of water to form an orange solution. 0.5 g of ZIF-8 was added into the solution, and the mixture was stirred for 30 minutes at room temperature. Then, 2.0 mL of polyvinyl alcohol (PVA) solution (1 wt.%) was introduced. After stirring for 20 minutes, a solution of hydrazine (1.0 mL, excess) in 30 mL of water was added drop-wise for 60 min into the reaction mixture under strong stirring. Colour of the mixture turned to gray immediately upon addition. After stirring for another 60 minutes, the dark solid was isolated by filtration, washed 2 times with water (10 mL), one time with methanol followed by dry ether (10 mL) and dried overnight under vacuum at 100°C. Pd on support (1.0 wt.%) was obtained as a gray powder, and stored under nitrogen atmosphere. ICP analysis showed 92-96%

palladium incorporation. BET specific surface area of the catalyst is found to be $1303 \text{ m}^2 \text{ g}^{-1}$. The sharp XRD peaks showed good crystallinity and were nearly identical to the support itself.¹⁴ The Pd nanoparticles having a size distribution of 4–9 nm are well distributed on the external surface of ZIF-8 and no obvious aggregation was observed.

General procedure for aminocarbonylation.

A 10 mL glass vial containing a magnetic stirrer bar was charged with a mixture of 1wt% Pd/ZIF-8 (24 mg, 0.21 mol% Pd), Xantphos (5.8 mg, 1.0 mol%), K_2CO_3 (345 mg, 2.5 mmol), aryl bromide (1.0 mmol) of DMHA.HCl, (1.5 mmol) and 2 mL of toluene. The vial was placed in a HEL CAT-7 pressure reactor, which was purged with nitrogen, followed by carbon monoxide and was filled with the required pressure (1–3 bar) of carbon monoxide. The reaction was continued with stirring for 12 h at 105 °C, cooled to room temperature and was analyzed by NMR after filtering through a short pad of Celite and evaporating the solvents and volatiles. In most cases the compound was nearly pure and was further purified by column chromatography using gradient elution with EtOAc:Hexane (10:1–1:1). No ligand was added when aryl iodide was used as the substrate instead of aryl bromide.

***N*-Methoxy-*N*,4-dimethylbenzamide⁷ (2a).** The general procedure was followed by using *p*-bromotoluene (171 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 173.6 mg (0.97 mmol, 97%). ¹H NMR (400 MHz, CDCl_3): δ 2.37 (s, 3H), 3.34 (s, 3H), 3.55 (s, 3H), 7.19 (d, $J = 7.6$, 3H), 7.58 (d, $J = 7.6$, 3H); ¹³C NMR (100 MHz, CDCl_3): δ 21.5, 34.0, 61.0, 128.4, 128.8, 131.3, 141.0, 170.1. Compound **2a** was also obtained by aminocarbonylation of *p*-iodotoluene (218 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 168.2 mg (0.94 mmol, 94%).

***N*-Methoxy-*N*-methylbenzamide⁷ (2b).** The general procedure was followed by using bromobenzene (157 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 156.8 mg (0.95 mmol, 95%). ¹H NMR (400 MHz, CDCl_3): δ 3.35 (s, 3H), 3.54 (s, 3H), 7.36 – 7.46 (m, 3H), 7.65 (m, 2H); ¹³C NMR (100 MHz, CDCl_3): δ 33.9, 61.1, 128.1, 128.3, 130.7, 134.3, 170.1. Compound **2b** was also obtained by aminocarbonylation of *o*-iodotoluene (218 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a yellow oil 141.5 mg (0.79 mmol, 79%).

***N*,4-Dimethoxy-*N*-methylbenzamide²² (2c).** The general procedure was followed by using 1-methoxy-4-bromobenzene (187 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column

chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 183.2 mg (0.94 mmol, 94%). ¹H NMR (400 MHz, CDCl_3): δ 3.35 (s, 3H), 3.56 (s, 3H), 3.84 (s, 3H), 6.90 (d, $J = 7.6$, 3H), 7.72 (d, $J = 7.6$, 3H); ¹³C NMR (100 MHz, CDCl_3): δ 34.0, 55.5, 61.0, 113.4, 126.2, 130.7, 161.7, 169.5.

***N*-Methoxy-*N*,2-dimethylbenzamide²² (2d).** The general procedure was followed by using *o*-bromotoluene (171 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a yellow oil 134.2 mg (0.75 mmol, 75%). ¹H NMR (400 MHz, CDCl_3): δ 2.26 (s, 3H), 3.21 (s, 3H), 3.44 (s, 3H), 7.11 (m, 2H), 7.20 (m, 2H); ¹³C NMR (100 MHz, CDCl_3): δ 18.9, 32.9, 60.9, 125.3, 126.0, 129.0, 130.0, 134.6, 135.2, 170.8.

***N*,3,4-Trimethoxy-*N*-methylbenzamide²³ (2e).** The general procedure was followed by using 4-bromo-1,2-dimethoxybenzene (217 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 216.1 mg (0.96 mmol, 96%). ¹H NMR (400 MHz, CDCl_3): δ 3.29 (s, 3H), 3.51 (s, 3H), 3.84 (s, 3H), 3.85 (s, 2H), 6.81 (d, $J = 7.6$, 1H), 7.32 (m, 1H), 7.26 (s, 1H); ¹³C NMR (100 MHz, CDCl_3): δ 34.0, 55.9, 56.0, 60.9, 110.2, 112.1, 122.1, 126.1, 148.4, 151.2, 169.3.

***N*,3,4,5-Tetramethoxy-*N*-methylbenzamide²³ (2f).** The general procedure was followed by using 5-bromo-1,2,3-trimethoxybenzene (247 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless solid 242.2 mg (0.95 mmol, 95%). ¹H NMR (400 MHz, CDCl_3): δ 3.31 (s, 3H), 3.56 (s, 3H), 3.84 (s, 9H), 6.93 (s, 2H); ¹³C NMR (100 MHz, CDCl_3): δ 34.0, 56.3, 60.9, 61.2, 106.0, 129.1, 140.2, 152.8, 169.4. Compound **2f** was also obtained by aminocarbonylation using 5-iodo-1,2,3-trimethoxybenzene (294 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a white solid 232.1 mg (0.91 mmol, 91%).

4-Chloro-*N*-methoxy-*N*-methylbenzamide⁷ (2g). The general procedure was followed by using *p*-chlorobromobenzene (191.5 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 187.1 mg (0.94 mmol, 94%). ¹H NMR (400 MHz, CDCl_3): δ 3.24 (s, 3H), 3.43 (s, 3H), 7.27 (d, $J = 7.6$, 3H), 7.56 (d, $J = 7.6$, 3H); ¹³C NMR (100 MHz, CDCl_3): δ 33.3, 60.9, 128.1, 129.7, 132.3, 136.5, 168.4.

4-Fluoro-*N*-methoxy-*N*-methylbenzamide²⁴ (2h). The general procedure was followed by using *p*-bromofluorobenzene (175 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 140.9 mg

(0.77 mmol, 77%). ^1H NMR (400 MHz, CDCl_3): δ 3.35 (s, 3H), 3.53 (s, 3H), 7.05 (m, 2H), 7.73 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.7, 61.1, 115.2 (d, $J = 21.8$ Hz), 130.1 (d, $J = 83.4$ Hz), 130.9 (d, $J = 8.6$ Hz), 164.2 (d, $J = 251.1$ Hz), 168.8.

***N*-Methoxy-*N*-methyl-4-nitrobenzamide²⁴ (2i).** The general procedure was followed by using 1-bromo-4-nitrobenzene (202 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 165.9 mg (0.79 mmol, 79%). ^1H NMR (400 MHz, CDCl_3): δ 3.33 (s, 3H), 3.49 (s, 3H), 7.78 (d, $J = 7.6$, 3H), 8.19 (d, $J = 7.6$, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.1, 61.4, 123.2, 129.2, 140.1, 148.8, 167.7. Compound **2i** was also obtained by aminocarbonylation of 1-iodo-4-nitrobenzene (249 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 201.4 mg (0.96 mmol, 96%).

4-Cyano-*N*-methoxy-*N*-methylbenzamide²³ (2j). The general procedure was followed by using 4-bromobenzonitrile (182 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 186.1 mg (0.98 mmol, 98%). ^1H NMR (400 MHz, CDCl_3): δ 3.32 (s, 3H), 3.48 (s, 3H), 7.66 (d, $J = 7.6$, 3H), 7.73 (d, $J = 7.6$, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.2, 61.3, 114.1, 118.1, 128.8, 131.8, 138.3, 167.9.

4-Amino-*N*-methoxy-*N*-methylbenzamide²⁵ (2k). The general procedure was followed by using bromotoluene (172 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 122.3 mg (0.68 mmol, 68%). ^1H NMR (400 MHz, CDCl_3): δ 3.29 (s, 3H), 3.53 (s, 3H), 3.93 (s, 2H, br, NH_2), 6.57 (d, $J = 7.6$, 3H), 7.56 (d, $J = 7.6$, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 34.2, 60.7, 113.7, 122.8, 130.6, 149.3, 169.8.

4-Formyl-*N*-methoxy-*N*-methylbenzamide (2l). The general procedure was followed by using *p*-bromobenzaldehyde (185 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 162.1 mg (0.84 mmol, 84%). ^1H NMR (400 MHz, CDCl_3): δ 3.34 (s, 3H), 3.50 (s, 3H), 7.78 (d, $J = 7.6$, 3H), 7.88 (d, $J = 7.6$, 3H), 10.03 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.4, 61.3, 128.7, 129.3, 137.5, 139.8, 168.8, 191.7. HRMS (ESI TOF): calcd for $\text{C}_{10}\text{H}_{12}\text{NO}_3$ [$\text{M}+\text{H}$]⁺ 194.0812; found: 194.0811.

4-Acetyl-*N*-methoxy-*N*-methylbenzamide⁸ (2m). The general procedure was followed by using 1-(4-bromophenyl)ethan-1-one (199 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 161.5 mg (0.78 mmol, 78%). ^1H NMR (400 MHz, CDCl_3): δ 2.58 (s, 3H),

3.32 (s, 3H), 3.49 (s, 3H), 7.70 (d, $J = 7.6$, 2H), 7.94 (d, $J = 7.6$, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 26.7, 33.4, 61.2, 127.9, 128.5, 138.3, 138.4, 168.9, 197.4.

***N*-Methoxy-*N*-methylnicotinamide⁸ (2n).** The general procedure was followed by using 3-bromopyridine (158 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 157.6 mg (0.95 mmol, 95%). ^1H NMR (400 MHz, CDCl_3): δ 3.23 (s, 3H), 3.41 (s, 3H), 7.21 (ddd, $J = 7.9$, 4.9, 0.9 Hz, 1H), 7.88 (dt, $J = 7.9$, 2.0 Hz, 1H), 8.53 (dd, $J = 4.9$, 1.7 Hz, 1H), 8.80 (dd, $J = 2.2$, 1.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.0, 61.1, 122.8, 129.7, 135.9, 149.1, 151.2, 167.2.

***N*-Methoxy-*N*-methylpyrimidine-5-carboxamide²⁶ (2o).** The general procedure was followed by using 5-bromopyrimidine (159 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 163.8 mg (0.98 mmol, 98%). ^1H NMR (400 MHz, CDCl_3) δ 3.37 (s, 3H), 3.56 (s, 3H), 7.06 (s, 2H), 9.24 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.0, 61.6, 127.9, 156.8, 159.9, 164.9.

4-Hydroxy-*N*-methoxy-*N*-methylbenzamide²⁷ (2p). The general procedure was followed by using *p*-iodophenol (220 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 101.4 mg (0.56 mmol, 56%). ^1H NMR (400 MHz, CDCl_3): δ 3.35 (s, 3H), 3.55 (s, 3H), 6.82 (d, $J = 7.6$, 3H), 7.58 (d, $J = 7.6$, 3H), 8.59 (s, br, OH); ^{13}C NMR (100 MHz, CDCl_3): δ 34.5, 61.1, 115.3, 124.2, 130.7, 159.7, 170.2.

5-Formyl-*N*,2,3-trimethoxy-*N*-methylbenzamide (2q). The general procedure was followed by using 3-iodo-4,5-dimethoxybenzaldehyde (292 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a yellow solid 237.8 mg (0.94 mmol, 94%). ^1H NMR (400 MHz, CDCl_3): δ 3.31 (s, br, 3H), 3.46 (s, br, 3H), 3.90 (s, 3H), 3.92 (s, 3H), 7.36 (s, 1H), 7.43 (s, 1H), 9.83 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 32.3, 56.1, 61.3, 61.5, 111.4, 123.6, 130.5, 132.2, 151.0, 153.0, 167.8, 190.3. HRMS (ESI TOF): calcd for $\text{C}_{12}\text{H}_{16}\text{NO}_5$ [$\text{M}+\text{H}$]⁺ 254.1023; found: 254.1023.

4-Bromo-*N*-methoxy-*N*-methylbenzamide²⁴ (2r). The general procedure was followed by using 4-bromo-1-iodobenzene (283 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 214.7 mg (0.88 mmol, 88%). ^1H NMR (400 MHz, CDCl_3): δ 3.36 (s, 3H), 3.54 (s, 3H), 7.55 (d, $J = 7.6$, 3H), 7.58 (d, $J = 7.6$, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 33.7, 61.3, 125.3, 130.2, 131.4, 133.0, 168.9.

3-Bromo-*N*-methoxy-*N*-methylbenzamide²⁸ (2s). The general procedure was followed by using 3-bromo-1-iodobenzene (283 mg, 1.0 mmol) and DMHA.HCl (143.4 mg, 1.5 mmol) for 12 h at 105 °C. The product was isolated after

column chromatography (elution with hexane/ethyl acetate 10:1 – 1:1) as a colorless liquid 212.3 mg (0.85 mmol, 85%). ¹H NMR (400 MHz, CDCl₃): δ 3.29 (s, 3H), 3.49 (s, 3H), 7.22 (m, 1H), 7.48-7.62 (m, 2H), 7.7 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 33.5, 61.1, 121.9, 126.7, 129.6, 131.2, 133.5, 136.0, 168.1.

4-Bromobenzophenone²⁹ (**3**). An ether solution of phenylmagnesium bromide (3.0 M, 0.2 mL, 0.6 mmol) was introduced into a 10 mL of ether solution of 4-bromo-*N*-methoxy-*N*-methylbenzamide (97.6 mg, 0.4 mmol) under stirring at 0 °C and the reaction mixture was stirred overnight. The crude mixture was worked up with 20 mL of HCl (2 M) solution and 30 mL EtOAc. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 5:1) as a white solid 85.6 mg (0.328 mmol, 82%). ¹H NMR (400 MHz, CDCl₃): δ 7.44 – 7.55 (m, 2H), 7.56 – 7.65 (m, 3H), 7.68 (d, *J* = 8.7 Hz, 2H), 7.74 – 7.82 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 127.6, 128.5, 130.0, 131.6, 131.7, 132.7, 136.5, 137.3, 195.6.

***N*-(4-Benzoylphenyl)acetamide**¹⁸ (**4**). Dry dioxane (0.8 mL) was added to a mixture of 78.3 mg (0.3 mol) of **3**, acetamide (0.6 mmol), CuI (5.7 mg, 10 mol%), cyclohexane-1,2-diamine (6.8 mg, 20 mol%) and K₂CO₃ (125 mg, 0.9 mmol), in a 5 mL Schlenk flask. The reaction mixture was degassed using argon for 2 min and was heated at 120 °C for 24 h under stirring. The crude mixture was worked up with 20 mL of saturated NaCl solution and 30 mL EtOAc. The product was isolated after column chromatography (elution with hexane/ethyl acetate 10:1 – 2:1) as a white solid 53.8 mg (0.225 mmol, 75%). ¹H NMR (400 MHz, CDCl₃): δ 2.19 (s, 3H), 7.40 – 7.29 (m, 1H), 7.46 (m, 1H), 7.56 (d, *J* = 8.7 Hz, 1H) 7.70 – 7.59 (m, 2H), 8.24 (s, br, OH). ¹³C NMR (100 MHz, CDCl₃): δ 23.9, 117.9, 127.4, 129.0, 130.8, 131.4, 132.3, 137.0, 140.9, 167.6, 194.7.

4-Methoxybenzophenone (**8**)³⁰. A 10 mL glass vial containing a magnetic stirrer bar was charged with a mixture of 1wt% Pd/ZIF-8 (24 mg, 0.42 mol% Pd), Et₃N (303 mg, 3 mmol), iodobenzene (0.5 mmol) and (4-methoxyphenyl)boronic acid (0.75 mmol) and 2 mL of toluene. The vial was placed in a HEL CAT-7 pressure reactor, which was purged with nitrogen, followed by carbon monoxide and was filled with the required pressure of carbon monoxide. The reaction was continued with stirring for 24 h at 105 °C, cooled to room temperature and was analyzed by NMR after filtering through a short pad of Celite and evaporating the solvents and volatiles. The crude product was purified by column chromatography by gradient elution with EtOAc:Hexane (10:1 – 1:1) to provide the ketone (**8**) as a colorless solid, 83 mg (0.39 mmol, 78%). ¹H NMR (400 MHz, CDCl₃): δ: 3.88 (s, 3 H), 6.95-6.98 (m, 2 H), 7.47 (dd, *J* = 7.5, 7.9 Hz, 2 H), 7.54-7.59 (m, 1 H), 7.75 (dd, *J* = 1.4, 8.5 Hz, 2 H), 7.81-7.85 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ: 55.6, 113.7, 128.3, 129.8, 130.3, 131.9, 132.7, 138.5, 163.4, 195.6.

(3,4-Methylenedioxyphenyl)phenylmethanone (**11**)³¹. The procedure for the preparation of **8** was followed in a Parr reactor at 10 bar of CO by using bromobenzene (**2b**, 157 mg,

1.0 mmol), 3,4-(methylenedioxy)phenylboronic acid (**10**, 249 mg, 1.5 mmol), Pd/ZIF-8 (24 mg, 1 wt.%, 0.21 mol% Pd), Et₃N (606 mg, 6 mmol), and CataCXium A (10.8 mg, 2 mol%) in 7 mL dry toluene for 18 h at 120 °C. Purification by flash chromatography (PE:Et₂O= 10:1-1:1) gave 167.2 mg (0.74 mmol, 74%) of the ketone **11** as a yellow oil; ¹H NMR (400 MHz, CDCl₃): δ 6.05 (s, 2H), 6.85 (dq, *J* = 1.8, 1.1 Hz, 1H), 7.37 (dd, *J* = 9.1, 1.3 Hz, 2H), 7.46 (ddd, *J* = 8.1, 6.6, 1.2 Hz, 2H), 7.52- 7.60 (m, 1H), 7.68-7.78 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 101.9, 107.8, 110.0, 126.9, 128.3, 129.8, 132.1, 138.3, 148.1, 151.6, 195.2.

Recycle experiments

The recycle experiments were conducted using the isolated catalyst after the standard aminocarbonylation of *p*-iodotoluene. The catalyst was isolated by centrifugation and decanting the solution, washed twice with fresh toluene and charged to the subsequent aminocarbonylation reaction.

Filtration test

Filtrate test³² was conducted by adding fresh reaction mixture (without the catalyst) to the filtrate of the standard aminocarbonylation reaction of iodotoluene.

Scale-up synthesis

Scale-up reactions were conducted in a Parr 25 mL Hastelloy-C high pressure reactor. 5 mmol of *p*-iodotoluene in 10 mL of toluene was added to 24 mg of 1wt%Pd/ZIF-8, 2.5 equiv of K₂CO₃, and 7.5 mmol *N,O*-dimethylhydroxyamine hydrochloride and charged to the Parr reactor. After purging with nitrogen, 3 bar carbon monoxide was charged and the reaction was carried out for 24 h at 105 °C. The reactor was cooled to room temperature and the reaction mixture was analyzed by GC and NMR for product after filtering off the catalyst and inorganic materials. Similarly, the scale up of *p*-bromotoluene was conducted in the presence of Xantphos ligand.

Acknowledgements

This work was funded by “GSK-EDB Singapore Partnership for Green and Sustainable manufacturing” and the Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology and Research (A*STAR), Singapore.

Notes and references

Institute of Chemical and Engineering Sciences, 8 Biomedical Grove, #07-01 Neuros, Singapore 138665. Fax: +65-6464-2102; Tel: +65-6799-8527; E-mail: abdul_seayad@ices.a-star.edu.sg

† Electronic Supplementary Information (ESI) available: [¹H and ¹³C NMR Spectra of compounds, HRMS of 2l & 2p, recycle and leaching studies]. See DOI: 10.1039/b000000x/

- (a) Kollar, L. *Modern Carbonylation Methods*; Wiley-VCH: Weinheim, 2008; (b) S. Sumino, A. Fusano, T. Fukuyama, and I.

- Ryu, *Acc. Chem. Res.*, 2014, dx.doi.org/10.1021/ar500035q; (c) S. T. Gadge and B. M. Bhanage, *RSC Adv.*, 2014, **4**, 10367; (d). X. –F. Wu, H. Neumann and M. Beller, *Chem. Soc. Rev.*, 2011, **40**, 4986. (e) X. Feng, J. Song, H. Liu, L. Wang, X. Yu and M. Bao, *RSC Adv.*, 2013, **3**, 18985.
- 2 (a) A. Kamal, N. Shankaraiah, N. Markandaya, L. K. Reddy and S. Reddy, *Tetrahedron Lett.*, 2008, **49**, 1465; (b) T. Yoshino, F. Ng and S. J. Danishefsky, *J. Am. Chem. Soc.*, 2006, **128**, 14185; (c) L. Z. Dias and M. A. De Sousa, *Tetrahedron Lett.*, 2003, **44**, 562; (d) A. Zamri and M. A. Abdallah, *Tetrahedron*, 2000, **56**, 249; (e) J. Liu, N. Ikemoto, D. Petrillo and J. D. Armstrong, *Tetrahedron Lett.*, 2002, **43**, 8223; (f) D. A. Evans, S. W. Kaldor, T. K. Jones, J. Clardy and T. J. Stout, *J. Am. Chem. Soc.*, 1990, **112**, 7001; (g) B. N. Manjunath, N. P. Sane and I. S. Aidhen, *Eur. J. Org. Chem.*, 2006, 2851; (h) J.-M. Nuzillard, A. Boumendjel and G. Massiot, *Tetrahedron Lett.*, 1989, **30**, 3779; (i) C. Beney, A. Boumendjel and A. M. Mariotte, *Tetrahedron Lett.*, 1998, **39**, 5779; (j) K. Ando, *Synlett*, 2001, 1272; (k) S. Fortin, F. Dupont and P. Deslongchamps, *J. Org. Chem.*, 2002, **67**, 5437; (l) A. Avenzoza, C. Cativiela, J. M. Peregrina, D. Sucunza and M. M. Zurbano, *Tetrahedron: Asymmetry*, 2001, **12**, 1383; (m) K. E. Rodrigues, *Tetrahedron Lett.*, 1991, **32**, 1275; (n) V. Selvamurugan and I. S. Aidhen, *Tetrahedron*, 2001, **57**, 6065; (o) V. Selvamurugan, and I. S. Aidhen, *Synthesis*, 2001, 2239; (p) T. Olpp and R. Bruckner, *Angew. Chem. Int. Ed.*, 2005, **44**, 1553; (q) K. R. Prasad and A. Chandrakumar, *Tetrahedron*, 2007, **63**, 1798; (r) K. R. Prasad and P. Anbarasan, *Tetrahedron: Asymmetry*, 2006, **17**, 2465; (s) K. R. Prasad and P. Anbarasan, *J. Org. Chem.*, 2007, **72**, 3155; (t) N. Satyamurthi, J. Singh, I. S. Aidhen, *Synthesis*, 2000, 375; (u) B. Sivaraman and I. S. Aidhen, *Synlett*, 2007, 959; Reviews on Weinreb amides, see: (v) M. Mentzel and H. M. R. Hoffmann, *J. Prakt. Chem.*, 1997, **339**, 517; (x) J. Singh, N. Satyamurthi and I. S. Aidhen, *J. Prakt. Chem.*, 2000, **342**, 340; (y) S. Balasubramaniam and I. S. Aidhen, *Synthesis*, 2008, **23**, 3707.
- 3 S. Nahm and S. M. Weinreb, *Tetrahedron Lett.*, 1981, **22**, 3815.
- 4 (a) T. Raghuram, S. Vijayaradhhi, J. Singh and I. Singh, *Synth. Commun.*, 1999, **29**, 3215; (b) F. D'Aniello, A. Mann and M. J. J. Taddei, *J. Org. Chem.*, 1996, **61**, 4870; (c) S. Nakamura, and M. Shibasaki, *Tetrahedron Lett.*, 1994, **35**, 4145; (d) M. Miyashita, Y. Toshimitu, T. Shiratani and H. Irie, *Tetrahedron: Asymmetry*, 1993, **4**, 1573; (e) M. Furber, M. E. Cooper and D. K. Donald, *Tetrahedron Lett.*, 1993, **34**, 1351; (f) R. S. Garigipati, D. M. Tschaen and S. M. Weinreb, *J. Am. Chem. Soc.*, 1985, **107**, 7790; (g) Y. Hamada, F. Yokokawa, M. Kabeya, K. Hatano, Y. Kuroono, T. Shiori, *Tetrahedron*, 1996, **52**, 8297; (h) J. A. Marshall, B. M. Seletsky and G. P. Luke, *J. Org. Chem.*, 1994, **59**, 3413; (i) M. Murakami, Y. Hoshino, H. Ito and Y. Ito, *Chem. Lett.*, 1998, 163.
- 5 (a) L. De Luca, G. Giacomelli and M. Taddei, *J. Org. Chem.*, 2001, **66**, 2534; (b) C. O. Kangani, D. E. Kelley and B. W. Day, *Tetrahedron Lett.*, 2006, **47**, 6289; (c) T. Niu, W. Zhang, D. Huang, C. Xu, H. Wang and Y. Hu, *Org. Lett.*, 2009, **11**, 4474; (d) I. Maugars, J. Poncet and P. Jouin, *Tetrahedron*, 1990, **46**, 2807; (e) M. Falorni, G. Giacomelli and A. M. Spanedda, *Tetrahedron: Asymmetry*, 1998, **9**, 3039; (f) J. Einhorn, C. Einhorn and J. L. Luche, *Synth. Commun.*, 1990, **20**, 1105; (g) M. Braun and D. Waldmuller, *Synthesis*, 1989, 856; (h) J. C. S. Woo, E. Fenster and G. R. Dake, *J. Org. Chem.*, 2004, **69**, 8984; (i) A. R. Tunoori, J. M. White and G. I. Georg, *Org. Lett.*, 2000, **2**, 4091; (j) M. P. Sibi, C. C. Stessman, J. A. Schultz, J. W. Christensen, J. Lu and M. Marvin, *Synth. Commun.*, 1995, **25**, 1255.
- 6 (a) A. Schoenberg and R. F. Heck, *J. Org. Chem.*, 1974, **39**, 3327, (b) A. Brennführer, H. Neumann and M. Beller, *Angew. Chem. Int. Ed.* 2009, **48**, 4114; (c) R. Grigg and S. P. Mutton, *Tetrahedron* 2010, **66**, 5515; (d) C. F. J. Barnard, *Organometallics* 2008, **27**, 5402; (e) S. Roy and G. W. Gribble, *Tetrahedron* 2012, **68**, 9867; (f) A. Schoenberg and R. F. Heck, *J. Org. Chem.* 1974, **39**, 3327; (g) Y. Uozumi, T. Arie and T. Watanabe, *J. Org. Chem.* 2001, **66**, 5272; (h) M. V. Khedkar, T. Sasaki and B. M. Bhanage, *ACS Catal.* 2013, **3**, 287; (i) S. Ho, G. Bondarenko, D. Rosa, B. Dragisic and A. Orellana, *J. Org. Chem.* 2012, **77**, 2008; (j) V. Fuente, C. Godard, C. Claver and S. Castillon, *Adv. Synth. Catal.* 2012, **354**, 1971; (k) Z. S. Qureshi, S. A. Revankar, M. V. Khedkar and B. M. Bhanage, *Catal. Today* 2012, **198**, 148. (l) F. Tinnis, O. Verho, K. P. Gustafson, C. W. Tai, J. E. Bäckvall, and H. Adolfsson, *Chem. – Eur. J.*, 2014, **20**, 5885. (m) H. Mei, J. Hu, S. Xiao, Y. Lei, and G. Li, *App. Catal. A: Gen.*, 2014, **475**, 40. (n) R. Skoda-Foldes and L. Kollar, *Curr. Org. Chem.*, 2002, **6**, 1097.
- 7 (a) J. R. Martinelli, D. M. M. Freckmann and S. L. Buchwald, *Org. Lett.*, 2006, **21**, 4843; (b) J. R. Martinelli, D. A. Watson, D. M. M. Freckmann, T. E. Barder and S. L. Buchwald, *J. Org. Chem.*, 2008, **73**, 7102.
- 8 A. Wiecekowska, R. Fransson, L. R. Odell and M. Larhed, *J. Org. Chem.*, 2011, **76**, 978.
- 9 A. Deagostino, P. Larini, E. G. Occhiato, L. Pizzuto, C. Prandi and P. Venturello, *J. Org. Chem.*, 2008, **73**, 1941.
- 10 A. Takács, A. Petz and L. Kollár, *Tetrahedron*, 2010, **66**, 4479.
- 11 (a) J. L. C. Rowsell, E. C. Spenser, J. Eckert, J. A. K. Howard and O. M. Yaghi, *Science*, 2005, **309**, 1350; (b) D. Bradshaw, A. Garai and J. Huo, *Chem. Soc. Rev.*, 2012, **41**, 2344.
- 12 (a) R. Banerjee, A. Phan, B. Wang, C. Knobler, H. Furukawa, M. O'Keeffe, O. M. Yaghi, *Science*, 2008, **319**, 939. (b) K. S. Park, Z. Ni, A. P. Côté, J. Y. Choi, R. Huang, F. J. U. Romo, H. K. Chae, M. O'Keeffe, and O. M. Yaghi, *Proc. Natl. Acad. Sci. U.S.A.* 2006, **103**, 10187.
- 13 (a) T. T. Dang, Y. Zhu, J. S. Y. Ngiam, S. C. Ghosh, A. Chen and A. M. Seayad, *ACS Catal.*, 2013, **3**, 1406; (b) T. T. Dang, Y. Zhu, S. C. Ghosh, A. Chen, C. L. L. Chai and A. M. Seayad, *Chem. Commun.*, 2012, **48**, 1805.
- 14 See [13a] for detailed characterization (SEM, TEM and XRD) of palladium nanoparticles on ZIF-8 (1wt.% Pd/ZIF-8) catalyst.
- 15 (a) D. S. Surry and S. L. Buchwald, *Chem. Sci.*, 2010, **1**, 13; (b) F. Monnier and M. Taillefer, *Angew. Chem. Int. Ed.*, 2009, **48**, 6954.
- 16 N. R. Ayyangar, R. J. Lahoti and T. Daniel, *Org. Prep. Proc. Int.*, 1991, **23**, 627.
- 17 (a) M. Cai, G. Ding, W. Hao and J. Peng, *Green Chem.*, 2011, **13**, 190; (b) H. Neumann, A. Brennfuehrer and M. Beller, *Chem. Eur. – J.*, 2008, **14**, 3645. (c) T. Hayashi, T. Ishiyama, H. Kizaki, N. Miyaura, A. Suzuki and A. Suzuki, *J. Org. Chem.*, 1998, **63**, 4726; (d) P. J. Tambade, Y. P. Patil, A. G. Panda, and B. M. Bhanage, *Eur. J. Org. Chem.*, 2009, 3022; (e) J.-J. Brunet and R. Chauvin, *Chem. Soc. Rev.*, 1995, **2**, 89; (f) A. Ahlburg, A. T. Lindhardt, R. H. Taaning, A. E. Modvig, and T. Skrydstrup, *J. Org. Chem.*, 2013, **78**, 10310; (g) K. M. Bjerglund, T. Skrydstrup, and G. A. Molander, *Org. Lett.*,

- 2014, **16**, 1888; (h) Z. S. Qureshi, K. M. Deshmukh, P. J. Tambade, and B. M. Bhanage, *Synthesis*, 2011, 243; (i) D. Mingji, B. Liang, C. Wang, Z. You, J. Xiang, G. Dong, J. Chen and Z. Yang, *Adv. Synth. Catal.* 2004, **346**, 1669; (j) E. Maerten, F. Hassouna, S. Couve-Bonnaire, A. Mortreux, J.-F. Carpentier and Y. Castanet, *Synlett*, 2003, **12**, 1874; (k) H. Li, M. Yang, Y. Qi and J. Xue, *Eur. J. Org. Chem.*, 2011, 2662; (l) M. Khedkar, P. J. Tambade, Z. S. Qureshi and B. M. Bhanage, *Eur. J. Org. Chem.*, 2010, 6981. (m) A. Petz, G. Peczey, Z. Pinter and L. Kollar, *J. Mol. Catal. A. Chem.* 2006, **255**, 97.
- 18 (a) T. Tagata, and M. Nishida, *J. Org. Chem.*, 2003, **68**, 9412.
- 19 (a) Z. Guo, C. Xiao, R. V. Maligal-Ganesh, L. Zhou, T. W. Goh, X. Li, D. Tesfagaber, A. Thiel, and W. Huang, *ACS Catal.* 2014, **4**, 1340; (b) H. -L. Jiang, B. Liu, T. Akita, M. Haruta, H. Sakurai, and Q. Xu, *J. Am. Chem. Soc.*, 2009, **131**, 11302. H. Furukawa, K. E. Cordova, M. O'Keeffe, O.M. Yaghi, *Science*, 2008, **319**, 939
- 20 (a) D. A. Conlon, B. Pipik, S. Ferdinand, C. R. LeBlond, J. R. Sowa Jr., B. Izzo, P. Collins, G.-J. Ho, J. M. Williams, Y.-J. Shi and Y. Sun, *Adv. Synth. Catal.*, 2003, **345**, 931; (b) S. P. Andrews, A. F. Stepan, H. Tanaka, S. V. Ley and M. D. Smitha *Adv. Synth. Catal.* 2005, **347**, 647; (c) J. P. Simeone, J. R. Sowa Jr., *Tetrahedron*, 2007, **63**, 12646; (d) H. Ke, H. Chen and G. Zao, *App. Organomet. Chem.*, 2013, **28**, 54; (e) S. Jayasree, A. Seayad, and R. V. Chaudhari, *Chem. Commun.*, 1999, 1067; (f) Y. Nishina, J. Miyata, R. Kawaib and K. Gotoh, *RSC Adv.*, 2012, **2**, 9380.
- 21 (a) A. S. Kashin and V. P. Ananikov, *J. Org. Chem.*, 2013, **78**, 11117. (b) A. Balanta, C. Godard and C. Claver, *Chem. Soc. Rev.*, 2011, **40**, 4973; (c) V. P. Ananikov and I. P. Beletskaya, *Organometallics*, 2012, **31**, 1595.
- 22 G. I. Georg, A. R. Tunoori and J. M. White, *Org. Lett.*, 2000, **2**, 4091.
- 23 B. Etienne, H. Abdallah, P.B. Jean-Francois and A. M. Jean-Daniel, *Org. Lett.*, 2010, **12**, 4042.
- 24 C. W. Muir, A. R. Kennedy, J. M. Redmond and A. J. B. Watson, *Org. Biomol. Chem.*, 2013, **11**, 3337.
- 25 K. Joong-Gon and J. D. Ok, *Bull. Korean Chem. Soc.*, 2010, **31**, 171.
- 26 C. Brands, G. Dolling and W. Kennedy, *Synthesis*, 2001, **12**, 1784.
- 27 M. Cowart, R. Faghih, M. P. Curtis, G. A. Gfesser, Y. L. Bennani, L. A. Black, L. Pan, K. C. Marsh, J. P. Sullivan, T. A. Esbenshade, G. B. Fox and A. A. Hancock, *J. Med. Chem.* 2005, **48**, 38.
- 28 C. Marlon, F. Ramin, C. P. Michael, G. A. Gregory, B. L. Youssef, B. A. Lawrence, P. Liping, M. C. Kennan, S. P. James, E. A. Timothy, F. B. Gerard and H. A. Arthur, *J. Med. Chem.*, 2005, **48**, 38.
- 29 T. Ishiyama, H. Kizaki, T. Hayashi, A. Suzuki and N. Miyaura, *J. Org. Chem.*, 1998, **63**, 4726.
- 30 M. Cai, J. Peng, L. Zha, and G. Zheng, *Eur. J. Org. Chem.*, 2009, 1585
- 31 (a) A. M., Echavarren and J. K. Stille, *J. Am. Chem. Soc.*, 1988, **110**, 1557; (b) H. Xu, K. Ekoue-Kovi, and C. Wolf, *J. Org. Chem.*, 2008, **73**, 7638.
- 32 N. T. S. Phan, M. Van Der Sluys and C. W. Jones, *Adv. Synth. Catal.*, 2006, **348**, 609.